GHK-Cu Dosage Calculator

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide first isolated from human plasma by Loren Pickart in 1973. The peptide consists of three amino acids — glycine, histidine, and lysine — with a high affinity for copper (Cu²⁺) ions, which it chelates into a stable complex. GHK is found at significant concentrations in plasma (~200 ng/mL in young adults), saliva, and urine, and its plasma concentration has been observed to decline significantly with age — from approximately 200 ng/mL in 20-year-olds to below 80 ng/mL in 60-year-olds — a finding that has driven research interest in its potential anti-aging applications.

GHK-Cu has been extensively studied for its effects on skin biology, wound healing, hair growth, and systemic tissue remodeling. In dermatological research, it has demonstrated an ability to stimulate collagen and glycosaminoglycan synthesis, promote angiogenesis, and exert antioxidant and anti-inflammatory effects. More recent bioinformatics research by Loren Pickart and collaborators has suggested GHK-Cu influences the expression of hundreds of genes involved in metabolic regulation, DNA repair, and programmed cell death, raising the possibility that its biological role is more systemic and fundamental than originally appreciated.

GHK-Cu acts through multiple converging mechanisms rather than a single defined receptor pathway. Its copper-chelating function appears to be central: copper-dependent enzymes including lysyl oxidase (involved in collagen and elastin crosslinking), superoxide dismutase (antioxidant), and cytochrome c oxidase (mitochondrial function) require bioavailable copper for proper function. GHK-Cu may serve as a biological delivery vehicle for copper to these enzyme systems.

Beyond copper delivery, GHK-Cu has been shown to directly stimulate fibroblast proliferation and collagen synthesis, upregulate VEGF and FGF-7 (keratinocyte growth factor) expression, enhance integrins involved in cell-matrix adhesion, and modulate the TGF-β signaling pathway involved in tissue remodeling. In gene expression studies using bioinformatics databases, GHK-Cu has been shown to reverse altered gene expression patterns associated with metastatic colon cancer and COPD back toward healthy signatures, suggesting broad biological regulatory activity.

Injectable GHK-Cu lyophilized powder is reconstituted with bacteriostatic water for injection. For a 50 mg vial, inject 5 mL of bacteriostatic water slowly against the glass wall, rest for 60 seconds, and swirl gently until dissolved. The solution may appear faintly blue-green due to the copper coordination complex — this is normal and expected. Do not discard or be alarmed by the coloration.

A 50 mg vial reconstituted with 5 mL gives 10,000 mcg/mL (10 mg/mL) — a highly concentrated solution suited to the milligram-range doses used in systemic GHK-Cu research. A 1 mg (1,000 mcg) dose requires 0.10 mL (10 IU on a U100 syringe), making doses easy to measure precisely. For subcutaneous administration in systemic research protocols, inject with a 27–31 gauge insulin syringe into the abdomen or upper thigh. For localized skin research, some protocols use intradermal micro-injections (mesotherapy technique), for which very fine gauge needles (30–32 gauge) are appropriate.

Injectable GHK-Cu research is less standardized than many other peptides because the compound is far more commonly studied in topical formulations (skincare products, hair growth serums) than as a systemic injectable. Topical concentrations in published skin research range from 0.01% to 3%, often in liposomal or nanoparticle carriers to enhance penetration.

For subcutaneous injectable research in systemic protocols, doses commonly discussed in the research community range from 500 mcg to 2 mg per day. Some researchers prefer every-other-day dosing at 1–2 mg given GHK-Cu's biological half-life is not long and systemic copper loading concerns are minimal at these doses. Research on wound healing in animal models has used topical applications of 1–100 mcg/mL at the wound site, applied daily.

Hair growth research has used scalp solutions containing 1–2% GHK-Cu applied topically twice daily. Injectable mesotherapy protocols for cosmetic research use localized microinjections of very dilute concentrations (0.1–1 mg/mL in a large volume) spread across treatment areas. There is currently no standardized injectable human research protocol in the peer-reviewed literature; all injectable dosing should be treated as exploratory.

Lyophilized GHK-Cu powder is quite stable and can be stored at room temperature for months when kept away from humidity and light, though refrigeration at 2–8°C is recommended for research use. Once reconstituted in bacteriostatic water, the copper-peptide complex solution should be refrigerated at 2–8°C and used within 28 days. The blue-green color should remain consistent; significant darkening may indicate oxidative degradation. Copper peptides are generally stable in solution at neutral pH when stored cold. Avoid exposure to strong oxidizing agents or alkaline conditions.

GHK-Cu has an excellent safety profile in topical applications, supported by decades of use in cosmetic formulations. Mild skin irritation can occur with high-concentration topical use. For injectable systemic research, no formal human safety studies of injectable GHK-Cu have been published. In vitro cytotoxicity studies show a U-shaped dose-response curve typical of copper compounds — GHK-Cu is beneficial at physiological concentrations and potentially cytotoxic at very high concentrations. Copper toxicity (hepatotoxicity) is a theoretical concern with excessive systemic doses, though the doses used in research protocols are many orders of magnitude below established copper toxicity thresholds. All research should be conducted with appropriate monitoring protocols.